Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.

Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E.

Leukemia. 2017 Mar;31(3):565-572. doi: 10.1038/leu.2016.267. Epub 2016 Oct 3.

PMID:
27694926
2.

NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.

Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, van Galen JF, Beverloo HB, Sonneveld E, Kaspers GJ, Trka J, Baruchel A, Zimmermann M, Creutzig U, Reinhardt D, Pieters R, Valk PJ, Zwaan CM.

Blood. 2011 Sep 29;118(13):3645-56. doi: 10.1182/blood-2011-04-346643. Epub 2011 Aug 2.

3.

NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.

Akiki S, Dyer SA, Grimwade D, Ivey A, Abou-Zeid N, Borrow J, Jeffries S, Caddick J, Newell H, Begum S, Tawana K, Mason J, Velangi M, Griffiths M.

Genes Chromosomes Cancer. 2013 Nov;52(11):1053-64. doi: 10.1002/gcc.22100. Epub 2013 Sep 2.

PMID:
23999921
4.

Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.

Thanasopoulou A, Tzankov A, Schwaller J.

Haematologica. 2014 Sep;99(9):1465-71. doi: 10.3324/haematol.2013.100917. Epub 2014 Jun 20.

5.

[Molecular Characteristics and Clinical Features of Adults with NUP98 Fusions in Acute Myeloid Leukemia].

Lun Y, Huang JC, Long D, Wang FF, Dai Y, Yang Y, Zhao TT, Li Q, Wu Y.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jul;49(4):575-581. Chinese.

PMID:
30378313
6.

NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.

Burillo-Sanz S, Morales-Camacho RM, Caballero-Velázquez T, Vargas MT, García-Lozano JR, Falantes JF, Prats-Martín C, Bernal R, Pérez-Simón JA.

Int J Lab Hematol. 2016 Feb;38(1):64-71. doi: 10.1111/ijlh.12435. Epub 2015 Sep 29.

PMID:
26418229
7.

High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.

Shiba N, Ohki K, Kobayashi T, Hara Y, Yamato G, Tanoshima R, Ichikawa H, Tomizawa D, Park MJ, Shimada A, Sotomatsu M, Arakawa H, Horibe K, Adachi S, Taga T, Tawa A, Hayashi Y.

Br J Haematol. 2016 Feb;172(4):581-91. doi: 10.1111/bjh.13869. Epub 2015 Dec 18.

PMID:
26684393
8.

Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization.

Nebral K, König M, Schmidt HH, Lutz D, Sperr WR, Kalwak K, Brugger S, Dworzak MN, Haas OA, Strehl S.

Haematologica. 2005 Jun;90(6):746-52.

9.

High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.

Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, Tsuchida M, Horibe K, Tsukimoto I, Adachi S, Kojima S, Hayashi Y.

Int J Hematol. 2012 Oct;96(4):469-76. doi: 10.1007/s12185-012-1163-1. Epub 2012 Aug 23.

PMID:
22915059
10.

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.

Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S.

Blood. 2014 Oct 9;124(15):2400-7. doi: 10.1182/blood-2014-04-570929. Epub 2014 Aug 21.

11.

MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.

Burillo-Sanz S, Morales-Camacho RM, Caballero-Velázquez T, Carrillo E, Sánchez J, Pérez-López O, Pérez de Soto I, González Campos J, Prats-Martín C, Bernal R, Vargas MT.

Eur J Haematol. 2018 May;100(5):436-443. doi: 10.1111/ejh.13037. Epub 2018 Mar 1.

PMID:
29384595
12.

Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.

Park SH, Lee HJ, Kim IS, Kang JE, Lee EY, Kim HJ, Kim YK, Won JH, Bang SM, Kim H, Song MK, Chung JS, Shin HJ.

Ann Lab Med. 2015 May;35(3):288-97. doi: 10.3343/alm.2015.35.3.288. Epub 2015 Apr 1.

13.

NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.

de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, Meshinchi S, van den Heuvel-Eibrink MM, Zwaan CM.

Leukemia. 2013 Dec;27(12):2280-8. doi: 10.1038/leu.2013.87. Epub 2013 Mar 27.

PMID:
23531517
14.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD.

J Clin Oncol. 2008 Nov 1;26(31):5078-87. doi: 10.1200/JCO.2008.17.5554. Epub 2008 Sep 22. Erratum in: J Clin Oncol. 2008 Dec 20;26(36):6021.

15.

A cryptic translocation leading to NUP98-PHF23 fusion in AML.

Ning Y.

Best Pract Res Clin Haematol. 2016 Dec;29(4):320-323. doi: 10.1016/j.beha.2016.10.002. Epub 2016 Oct 18. Review.

PMID:
27890253
16.

NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia.

Shiba N, Ichikawa H, Taki T, Park MJ, Jo A, Mitani S, Kobayashi T, Shimada A, Sotomatsu M, Arakawa H, Adachi S, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y.

Genes Chromosomes Cancer. 2013 Jul;52(7):683-93. doi: 10.1002/gcc.22064. Epub 2013 Apr 30.

PMID:
23630019
17.

NUP98-PHF23 fusion is recurrent in acute myeloid leukemia and shares gene expression signature of leukemic stem cells.

Ho H, Skaist AM, Pallavajjala A, Yonescu R, Batista D, Wheelan SJ, Ning Y.

Leuk Res. 2016 Jun;45:1-7. doi: 10.1016/j.leukres.2016.03.006. Epub 2016 Mar 30.

PMID:
27060678
18.

Multiplex fusion gene testing in pediatric acute myeloid leukemia.

Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, Tawa A, Takahashi H, Tomizawa D, Taga T, Kinoshita A, Adachi S, Horibe K.

Pediatr Int. 2018 Jan;60(1):47-51. doi: 10.1111/ped.13451.

PMID:
29105243
19.

Analysis of class I and II aberrations in Iraqi childhood acute myeloid leukemia using filter paper cards.

Al-Kzayer LF, Uyen le TN, Al-Jadiry MF, Al-Hadad SA, Al-Badri SA, Ghali HH, Ameen NA, Liu T, Matsuda K, Abdulkadhim JM, Al-Shujairi TA, Matti ZI, Hasan JG, Al-Abdullah HM, Al-Ani MH, Saber PA, Khalil HM, Inoshita T, Kamata M, Koike K, Sakashita K.

Ann Hematol. 2014 Jun;93(6):949-55. doi: 10.1007/s00277-014-2007-2. Epub 2014 Jan 25.

PMID:
24464319
20.

POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15).

Lisboa S, Cerveira N, Bizarro S, Correia C, Vieira J, Torres L, Mariz JM, Teixeira MR.

Mol Cancer. 2013 Jan 18;12:5. doi: 10.1186/1476-4598-12-5.

Supplemental Content

Support Center